CGON: CG Oncology, Inc. Operating Margin

Corporate emblem and logo of CG Oncology (CGON)

Complex bioengineering and patent protection create a significant barrier to entry in the bladder cancer therapy niche. The operating margin confirms this resilience, where the level of -4293.50 reflects the current magnitude. Scaling Phase 3 trials lays the foundation for global distribution, while technological leadership in creating oncolytic viruses guarantees the long-term market dominance of CG Oncology, Inc. (CGON).

CG Oncology (CGON): Operating Return on Sales from 02/21/2024 to 11/20/2026

Metric breakdowns and analytics for CG Oncology, Inc. (CGON)

Analysis of all company metrics:cgoncology.com
Core merchandise of CG Oncology Therapeutics

The specifics of CG Oncology, Inc. (CGON) require colossal expenditures on strictly regulated biomaterial logistics, which directly impacts operational efficiency. This core business margin indicator reflects the portion of revenue remaining after covering operating expenses before interest and taxes, allowing investors to assess the business's actual ability to generate value and the model's resilience to currency fluctuations.

Competitors of CG Oncology, Inc.

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|UroGen Pharma - Operating Sales Margin|Operating Profit Rate BCAX|PSNL - Operating Profitability|Profitability of Operations Erasca Oncology ERAS|delcath.com (DCTH) - Operating Profitability|Y-mAbs Therapeutics - Operating Profit Rate|AURA (Aura Biosciences Inc) - Operating Margin|Operating Return on Sales candeltx.com CADL|Operating Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Operating Profit Rate|Operating Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Operating Profitability|TuHURA Biosciences Inc. - Operating Margin|TARA - Operating Margin|FATE (Fate Therapeutics) - Operating Sales Margin|Operating Sales Margin Aadi Bioscience, Inc.|Operating Sales Margin TCRX|Operating Profitability CSBR|Operating Margin XBIT|Profitability of Operations CEL-SCI Corp.|Operating Profitability ostherapies.com OSTX|RADX: Return on Sales by Operating Profit|ARTV: Operating Sales Margin|ANL (Adlai Nortye) - Return on Sales by Operating Profit|Veru (VERU) - Operating Profitability|Operating Sales Margin Tempest Therapeutics Inc|Operating Profitability Xilio Therapeutics|Return on Sales by Operating Profit RENB (Renovaro Inc.)|Operating Profitability Mural Oncology PLC (MURA)|Operating Margin Kairos Pharma (KAPA)|Operating Profitability onkuretherapeutics.com OKUR|GDTC: Return on Sales by Operating Profit|CRIS: Operating Sales Margin|apollomicsinc.com (APLM) - Operating Sales Margin|THAR: Operating Margin|Operating Sales Margin Advanced Biomed Inc.|Operating Sales Margin GNPX|Return on Sales by Operating Profit CLDI (Calidi Biotherapeutics)|Operating Margin SBFM|Xenetic Biosciences, Inc. - Return on Sales by Operating Profit|Operating Profitability Salarius Pharmaceuticals SLRX|Operating Margin purple-biotech.com PPBT|AONC - Operating Profitability|BGNE: Operating Profitability|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin